Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck and Takeda form US and Japan CNS alliance

Lundbeck and Takeda form an alliance to develop and commercialise novel CNS compounds in the US and Japan for the treatment of mood and anxiety disorders

Danish pharmaceutical company Lundbeck and Japan-headquartered Takeda have formed an alliance to develop and commercialise novel CNS compounds in the US and Japan for the treatment of mood and anxiety disorders.

Lundbeck has several compounds in its pipeline and the partnership will at first focus on co-development and co-commercialisation of the two most advanced: LU AA21004 and LU AA24530. The agreement sets out an option under certain conditions to include two other compounds of the same class in earlier stages of development.

Both later-stage compounds belong to a new chemical class and have demonstrated fast onset of effect and increased efficacy. The most advanced compound, LU AA21004, is currently in clinical phase II development for the treatment of major depressive disorder (MDD). Lundbeck says the clinical trials will be finalised, opened and announced in Q4 2007.

Per the agreement, Lundbeck will receive an initial payment of USD 40m and a potential maximum of USD 345m in additional development milestone payments.

Both firms will complete development programmes, with Takeda funding sales and the majority of the remaining development activities. 

Lundbeck will receive a share of the revenue generated in the US and Japan, as well as royalty payments on Takeda's share of revenues. Other financial details were undisclosed.

Yasuchika Hasegawa, president and CEO of Takeda, said: "We are delighted to have reached an agreement with one of the strongest global players in central nervous system research. We believe the [novel] compounds have the potential to demonstrate substantial benefits compared with existing therapies and that they willÖ enhance our CNS franchise, which is one of our core therapeutic areas."

Dr Claus Braestrup, president and CEO of Lundbeck, said: "The agreement provides a unique opportunity for Lundbeck to build a commercial presence both in the US and in Japan with the support of a strong partner, while we continue to utilise our own European and international platform outside the US and Japan to commercialise the compounds."

5th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics